Cycling for a Cure: The Impact of MMRF's Road to Victories Program on Multiple Myeloma Research

The Multiple Myeloma Research Foundation (MMRF) is set to host its eighth annual Road to Victories endurance cycling program, a pivotal event that combines the spirit of athleticism with the noble cause of funding research for multiple myeloma. Scheduled to begin on August 24, 2024, this year's journey through California's Wine Country is more than just a test of endurance; it's a lifeline for those battling this form of blood cancer.

Since its launch in 2017, the program has seen remarkable participation, with 160 cyclists, including 31 multiple myeloma patients, completing the rides. This event has become a symbol of hope, uniting patients, caregivers, healthcare professionals, and supporters from Johnson & Johnson, the program's sponsor, in a shared mission to conquer multiple myeloma.

The financial impact of Road to Victories is undeniable, with over $2 million raised to date. These funds are instrumental in advancing the MMRF's mission, contributing to more than $600 million committed to research and programs. The results speak volumes: 15+ FDA-approved therapies have been developed, significantly extending the life expectancy of patients, alongside the initiation of nearly 100 clinical trials and the creation of the CoMMpass dataset, a groundbreaking resource in cancer research.

Michael Andreini, MMRF's President and CEO, highlights the dual significance of the event: it's a testament to the cyclists' dedication and a critical fundraiser that fuels the foundation's efforts. The partnership with Johnson & Johnson underscores the vital role of collaboration in medical research, with Tyrone Brewer of Johnson & Johnson Innovative Medicine envisioning a future where multiple myeloma is curable.

As cyclists from across the nation prepare for this year's event, their journey is a powerful reminder of the collective effort required to tackle such a formidable disease. The Road to Victories program exemplifies how determination and philanthropy can drive scientific breakthroughs, offering hope to the multiple myeloma community and paving the way for a cure.